Antonio Palumbo, MD, of the University of Torino, discusses in Italian this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4).
Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discuss findin...
A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs ...
Nikhil Wagle, MD, of the Dana-Farber Cancer Institute, discusses the strides made in this national direct-to-patient initiative to accelerate genomics research (Abstract LBA1519).
Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant...